The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of irinotecan and cisplatin combination as first-line chemotherapy in patients with advanced esophageal squamous-cell carcinoma: An interim report.
Xiaodong Zhang
Disclosure not yet available
Lin Shen
Disclosure not yet available
Xiaotian Zhang
Disclosure not yet available
Jie Li
Disclosure not yet available
Yan Li
Disclosure not yet available
Jian Li
Disclosure not yet available
Jun Zhou
Disclosure not yet available
Zhihao Lu
Disclosure not yet available
Ming Lu
Disclosure not yet available